Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease  Markus Peck–Radosavljevic, John Boletis, Fatih Besisik, Maria Lúcia Ferraz, Laurent Alric, Didier Samuel, Diethelm Messinger, Andreas Tietz, Hugo Cheinquer  Clinical Gastroenterology and Hepatology  Volume 9, Issue 3, Pages 242-248 (March 2011) DOI: 10.1016/j.cgh.2010.10.018 Copyright © 2011 AGA Institute Terms and Conditions

Figure 1 Patient flow diagram. Clinical Gastroenterology and Hepatology 2011 9, 242-248DOI: (10.1016/j.cgh.2010.10.018) Copyright © 2011 AGA Institute Terms and Conditions

Figure 2 Predictive value of undetectable HCV RNA(<50 IU/mL) at week 12 for SVR in the 135 μg/wk group(top) and in the 90 μg/wk group(bottom). Patients with missing HCV RNA results at week 12 are excluded from the analysis. Clinical Gastroenterology and Hepatology 2011 9, 242-248DOI: (10.1016/j.cgh.2010.10.018) Copyright © 2011 AGA Institute Terms and Conditions